---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000070"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:19:42.675863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY

## Summary
- Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.
- GAAP EPS $0.32 (down from $0.34), adjusted EPS $0.63 (vs guidance $0.57-0.59).
- Cardiovascular segment grew 25.0% reported; MedSurg grew 10.3%.
- Full-year 2024 organic sales guidance ~15%; Q4 organic guidance 14-16%.
- Completed acquisition of Silk Road Medical for stroke prevention.

## SEC filing metadata
- accession: 0000885725-24-000070
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/0000885725-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/bsx-20241023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000070
- JSON: https://secwatch.observer/filing/0000885725-24-000070.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.